Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder

Figures & data

Table 1. Differences in clinical event rates among patients with schizoaffective disorder treated with paliperidone palmitate (PP1M) vs placebo.

	PP1M therapy per patient-year [CI]	PP1M monotherapy per patient-year [CI]	PP1M adjunctive therapy per patient-year [CI]
Relapse	−18.3% [−25.1%, −11.9%]	−21.3% [−28.4%, −11.9%]	−15.4% [−24.8%, −3.4%]
Serious treatment-emergent adverse event (TEAE)	−3.9% [−6.9%, 2.7%]	−3.9% [−6.9%, 2.7%]	−3.9% [−6.9%, 2.7%]
Other non-serious TEAE	12.7% [1.7%, 26.2%]	12.7% [1.7%, 26.2%]	12.7% [1.7%, 26.2%]

Negative numbers indicate a reduced clinical event rate vs placebo.

CI, confidence interval.

Table 2. Annual medical cost differences among patients with schizoaffective disorder: paliperidone palmitate (PP1M) vs placebo.

	PP1M therapy ($/patient-year)	PP1M monotherapy ($/patient-year)	PP1M adjunctive therapy ($/patient-year)
Relapse	−$7071	−$8252	−$5962
Serious treatment-emergent adverse event (TEAE)	−$82	−$82	−$82
Other non-serious TEAE	$13	$13	$13
Total medical cost	−$7140	−$8321	−$6031

Negative numbers indicate a cost reduction vs placebo

Figure 1. Univariate sensitivity analyses of total annual medical cost differences: paliperidone palmitate (PP1M) vs placebo.

Figure 2. Distribution of total annual medical cost differences from 10,000 cycles of Monte Carlo simulation: paliperidone palmitate vs placebo.